The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Sun., Apr. 18, 5:41 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #82. Spectrum Pharmaceuticals Allos Therapeutics

Acquirer: Spectrum Pharmaceuticals (SPPI)
Acquiree: Allos Therapeutics (ALTH)
Details: Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology today announced the successful completion of the acquisition of Allos Therapeutics, Inc., on September 5, 2012 through a "short-form" merger of Sapphire Acquisition Sub, Inc., a wholly-owned subsidiary of Spectrum, with and into Allos with Allos surviving the merger and continuing as a wholly-owned subsidiary of Spectrum.

Spectrum Pharmaceuticals is a biopharma company. Co.'s product portfolio consists of in-development drug products for the treatment of cancer patients. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients (including diffuse large B-cell lymphoma).

SPPI SEC Filing Email Alerts Service


Open the SPPI Page at The Online Investor »

Spectrum Pharmaceuticals is a biopharma company. Co.'s product portfolio consists of in-development drug products for the treatment of cancer patients. Co. has three drugs in development: ROLONTIS, which is a long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in development for treating relapsed or refractory non-Hodgkin's lymphoma patients (including diffuse large B-cell lymphoma).

SPPI SEC Filing Email Alerts Service


Open the ALTH Page at The Online Investor »

Company Name: 
Spectrum Pharmaceuticals Inc
Stock buyback: 
SPPI buyback
Website: 
www.sppirx.com
Sector: 
Biotechnology
Number of ETFs Holding SPPI: 
40
Total Market Value Held by ETFs: 
$121.11M
Total Market Capitalization: 
$459.00M
% of Market Cap. Held by ETFs: 
26.38%
Company Name: 
Allos Therapeutics Inc
Website: 
www.allos.com
Sector: 
Biotechnology
 

Quotes delayed 20 minutes


Biotechnology M&A - Slide 82 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.